Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular–Orthomolecular Strategies
Cancers · 30.04.2026 · 18 (9) · 1435
DOI: 10.3390/cancers18091435 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.04.2026. Verfasst von Marijana Turčić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Teaching Institute of Public Health of Primorsko-Goranska County, Krešimirova 52a, 51000 Rijeka, Croatia. Die Arbeit nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is acknowledged as a heterogeneous malignancy underlined by complex genetic, metabolic, and immune dysregulation. In particular, molecular studies have revealed distinct oncogenic mechanisms that have been exploited and studied as therapeutic intervention targets. These include hypoxia-driven signaling, chromosomal translocations, and gene fusion events that affect tumor progression. This review provides a comprehensive overview of these targets and rethinks RCC management. Therapeutic concepts include the targeting of genomic fusion biology with emerging cell-based immunotherapies or targeted molecular inhibition, and orthomolecular therapeutic strategies are presented. Two clinical and pathological features are highlighted—namely, the TFE3 fusion proteins in translocation RCC and the growing role of hypoxia-inducible factor-2α (HIF-2α) inhibitors in clear-cell RCC. We also present recent data on novel immunotherapeutic approaches, including autologous hematopoietic stem and progenitor cell-based interferon-α gene therapy, as well as chimeric antigen receptor T-cell therapy. These therapies are discussed in light of their mechanistic rationale, translational potential, and existing clinical challenges due to unwanted side effects. At last, orthomolecular and natural product-based therapies are reviewed for their potential as adjunctive therapies that might be used for oxidative stress management, the targeting of tumor metabolism and immune effects, and to increase standard treatment tolerance. This review points to a multidimensional framework that might support further research and studies in precision-guided RCC management, as integrative approaches may enhance therapeutic efficacy, reduce toxicity, and support the development of personalized interventions for advanced or treatment-resistant RCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Teaching Institute of Public Health of Primorsko-Goranska County, Krešimirova 52a, 51000 Rijeka, Croatia.
- Department of Urology, Clinical Hospital Center Rijeka, Tome Strižića 3, 51000 Rijeka, Croatia.
- Department of Urology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia.
- Department of Oncology and Hematology, General Hospital Pula, Santorijeva 24a, 52200 Pula, Croatia.
- Faculty of Medicine, Juraj Dobrila University of Pula, Zagrebačka 30, 52100 Pula, Croatia.
- International Academy of Science and Arts in Bosnia and Herzegovina, Radnička cesta, 71000 Sarajevo, Bosnia and Herzegovina.
ORCID-Profile: Marijana Turčić, Krešimir Pavelić, Sandra Kraljević Pavelić
Förderung
- European Union
Zitieren
APA
Turčić, M., Krpina, K., Trivanović, D., Pavelić, K., & Kraljević Pavelić, S. (2026). Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular–Orthomolecular Strategies. Cancers, 18(9), 1435. https://doi.org/10.3390/cancers18091435
Vancouver
Turčić M, Krpina K, Trivanović D, Pavelić K, Kraljević Pavelić S. Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular–Orthomolecular Strategies. Cancers. 2026;18(9):1435. doi:10.3390/cancers18091435
BibTeX
@article{Turi2026,
author = {Turčić, Marijana and Krpina, Kristian and Trivanović, Dragan and Pavelić, Krešimir and Kraljević Pavelić, Sandra},
title = {Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular–Orthomolecular Strategies},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1435},
doi = {10.3390/cancers18091435}
}
EUVIMED